Changchun Zhuoyi Biological Co., Ltd. signed a successful contract with the Institute of Basic Medicine of the Chinese Academy of Medical Sciences.

Guide: Exclusive patent access to human papillomavirus (HPV) universal vaccine technology.
, Changchun Zhuoyi Biological Co., Ltd. successfully signed a contract with the Institute of Basic Medicine of the Chinese Academy of Medical Sciences, thus obtaining exclusive patent rights, product development and market rights for hpvvirus (HPV) universal vaccine technology.
Zhuoyi creature this move, from the true sense of the interpretation of science and technology, from scientific research to production of the transformation, with practical action to perfectly demonstrate the scientific and technological service to the far-sightedness of human beings.
HPV is a typical tumor virus that can cause good malignant lesions of epithelial tissue.
especially in recent years, the incidence and mortality rate of cervical cancer in China is on the rise, and the age of onset tends to be younger.
at this stage there are more than 200 types of HPV, of which more than 20 are carcinogenic, inducing about 100% cervical cancer, 88% anal cancer, 43% vulva cancer, 70% vaginal/penis cancer and 72% head and neck cancer, including 12 common high-risk types (HPV16, -18, -31, -33, -35, -45, -52, -58, etc.), and more than 10 rare carcinogenic types.
at the same time, low-risk HPV and skin-type HPV will also induce a variety of diseases, including mucosal warts and other benign lesions, warts, respiratory recurrent papilloma, skin warts and other diseases.
cervical cancer is the third highest incidence of malignant tumors in women.
.